187 related articles for article (PubMed ID: 1662027)
1. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis.
Sreedharan S; Peterson LR; Fisher LM
Antimicrob Agents Chemother; 1991 Oct; 35(10):2151-4. PubMed ID: 1662027
[TBL] [Abstract][Full Text] [Related]
2. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.
Sreedharan S; Oram M; Jensen B; Peterson LR; Fisher LM
J Bacteriol; 1990 Dec; 172(12):7260-2. PubMed ID: 2174869
[TBL] [Abstract][Full Text] [Related]
3. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.
Li Z; Deguchi T; Yasuda M; Kawamura T; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
Antimicrob Agents Chemother; 1998 Dec; 42(12):3293-5. PubMed ID: 9835531
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
5. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
6. Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus.
Tankovic J; Duval J; Courvalin P
FEMS Immunol Med Microbiol; 1994 Jun; 9(1):35-9. PubMed ID: 7920462
[TBL] [Abstract][Full Text] [Related]
7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
8. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
Ito H; Yoshida H; Bogaki-Shonai M; Niga T; Hattori H; Nakamura S
Antimicrob Agents Chemother; 1994 Sep; 38(9):2014-23. PubMed ID: 7811012
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
10. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
[TBL] [Abstract][Full Text] [Related]
11. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of quinolones against coagulase-negative staphylococci and the quinolone resistance-determining region of the gyrA genes from six species.
Takahata M; Yonezawa M; Matsubara N; Watanabe Y; Narita H; Matsunaga T; Igarashi H; Kawahara M; Onodera S; Oishi Y
J Antimicrob Chemother; 1997 Sep; 40(3):383-6. PubMed ID: 9338491
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
[TBL] [Abstract][Full Text] [Related]
14. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
15. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
16. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin resistance in Campylobacter jejuni isolates: detection of gyrA resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysis.
Zirnstein G; Li Y; Swaminathan B; Angulo F
J Clin Microbiol; 1999 Oct; 37(10):3276-80. PubMed ID: 10488192
[TBL] [Abstract][Full Text] [Related]
18. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
19. Different susceptibility of coagulase-positive and coagulase-negative staphylococci to ciprofloxacin.
Utili R; Tripodi MF; Rosario P; Andreana A; Locatelli A; Rambaldi A; Florio A
New Microbiol; 1996 Oct; 19(4):309-14. PubMed ID: 8914131
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
